Trials / Withdrawn
WithdrawnNCT04499352
A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer
An Open Label, Randomized Phase II Study of BI 754091 Alone or in Combination With BI 836880 in Patients With Chemotherapy Resistant, Unresectable, Metastatic Squamous Cell Carcinoma of the Anal Canal
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this trial is to assess anti-tumour activity of BI 754091 as monotherapy and of BI 754091 in combination with BI 836880 in patients with unresectable or metastatic squamous cell carcinoma of the anal canal who progressed on or after chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 754091 | BI 754091 |
| DRUG | BI 836880 | BI 836880 |
Timeline
- Start date
- 2020-09-14
- Primary completion
- 2020-10-19
- Completion
- 2020-10-19
- First posted
- 2020-08-05
- Last updated
- 2021-11-15
Locations
1 site across 1 country: South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04499352. Inclusion in this directory is not an endorsement.